BridgeBio Oncology Therapeutics, Inc. BBOT
At closeNov 6, 2026, 6:02 PM EST
After hours · Nov 6, 6:02 PM ET
- YTD
- -83.71%
- 1 year
- -83.35%
- Market cap
- 163.56M
- EPS (ttm)
- -0.07
- Shares out
- 79.20M
- YTD return
- -83.71%
- 1-year return
- -83.35%
- Volume
- 687.05K
- Avg volume
- 559.55K
- Open
- 2.19
- Previous close
- 2.17
- Day's range
- 1.99 – 2.25
- 52-week range
- 2.04 – 13.73
- Analysts
- Strong Buy
- Price target
- 24.20 (+1086.3%)
5D -0.58 (-22.14%)
Key statistics
- Enterprise value
- 227.79M
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- 0
- Total cash
- 131.40M
- Total debt
- 2.83M
- Return on equity
- 0.00%
- Short % of float
- 0.00%
- 50-day average
- 11.45
- 200-day average
- 10.84
Analyst view
Consensus: strong buy
- Target (low)
- 21.00
- Target (mean)
- 24.20
- Target (high)
- 27.00
- Strong buy1
- Buy4
- Hold0
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate -0.416.
Financials — quick view
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 13, 2025 | Oppenheimer | main | Outperform | Outperform |
| Sep 17, 2025 | Leerink Partners | init | — | Outperform |
| Sep 15, 2025 | HC Wainwright & Co. | init | — | Buy |
| Sep 4, 2025 | Oppenheimer | init | — | Outperform |
| Aug 18, 2025 | Wedbush | init | — | Outperform |
About BridgeBio Oncology Therapeutics, Inc.
BridgeBio Oncology Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of small-molecule therapeutics targeting renin-angiotensin system and phosphoinositide 3-kinase malignancies. The company's product pipeline includes BBO-8520, a direct inhibitor targeting the on and off states of KRAS that is in Phase I clinical trial to treat patients with KRASG12C mutant non-small cell lung cancer; and BBO-10203, an orally bioavailable small molecule that is in Phase I clinical trial for treatment of patients with HER2+ breast cancer, HR+/HER2- breast cancer, KRAS pancreatic ductal adenocarcinoma (PDAC), KRAS mutant colorectal cancer (CRC), and KRAS mutant NSCLC. It is also developing BBO-11818, an orally bioavailable pan KRAS on/off inhibitor that is in Phase I clinical trial to treat patients with KRASG12D and KRASG12V mutant NSCLC, PDAC, and CRC. The company was founded in 2016 is headquartered in South San Francisco, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- bbotx.com
News
Morgan Stanley Maintains Overweight on BridgeBio Oncology, Lowers Price Target to $13 
Oppenheimer Maintains Outperform on BridgeBio Oncology, Lowers Price Target to $16 
12 Health Care Stocks Moving In Thursday's Intraday Session 
Leerink Partners Maintains Outperform on BridgeBio Oncology, Lowers Price Target to $27 
Canaccord Genuity Maintains Buy on BridgeBio Oncology, Lowers Price Target to $20 
Raymond James Maintains Outperform on BridgeBio Oncology, Lowers Price Target to $22 
12 Health Care Stocks Moving In Wednesday's Intraday Session - Stifel Maintains Buy on BridgeBio Oncology, Lowers Price Target to $15
- Wedbush Reiterates Outperform on BridgeBio Oncology, Maintains $25 Price Target
Bridgebio Announces New KRASG12C Data And Strategic Prioritization Of BBO-8520 In Combination With Checkpoint Inhibitor In 2L+ KRASG12C Inhibitor-Experienced NSCLC Patients And BBO-11818 And BBO-10203 In KRAS-Mutant Cancers
Your note
Sign in to keep a note on BBOT — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| CHEN BIHUA X. | Director and Beneficial Owner of more than 10% of a Class of Security | Stock Award(Grant) | Aug 10, 2025 | 0 |
| HELIX HOLDINGS II L.L.C. | Beneficial Owner of more than 10% of a Class of Security | Stock Award(Grant) | Feb 12, 2024 | 0 |
| HOLMAN ALBERT A III | Former | Conversion of Exercise of derivative security | Aug 10, 2025 | 30,000 |
| MCKENNA MARK C | Former | Conversion of Exercise of derivative security | Aug 10, 2025 | 30,000 |
| SCHMID JOHN P | Former | Conversion of Exercise of derivative security | Aug 10, 2025 | 30,000 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Alphabet Inc. | 3.56% | 2,823,126 | 34.95M | Sep 29, 2025 |
| Blackrock Inc. | 2.59% | 2,048,552 | 25.36M | Sep 29, 2025 |
| Vanguard Group Inc | 0.82% | 647,599 | 8.02M | Sep 29, 2025 |
| Aisling Capital Management LP | 0.71% | 564,625 | 6.99M | Sep 29, 2025 |
| Geode Capital Management, LLC | 0.68% | 541,602 | 6.71M | Sep 29, 2025 |
| SilverArc Capital Management, LLC | 0.58% | 457,414 | 5.66M | Sep 29, 2025 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| BlackRock Funds-BLACKROCK HEALTH SCIENCES OPPORTUNITIES PORTFOLIO | 1.06% | 841,293 | 10.42M | Aug 30, 2025 |
| Fidelity Concord Street Trust-Fidelity Extended Market Index Fund | 0.32% | 251,285 | 3.11M | Sep 29, 2025 |
| Fidelity Select Portfolios-Select Biotechnology Portfolio | 0.17% | 134,677 | 1.67M | Sep 29, 2025 |
| Fidelity Concord Street Trust-Fidelity Total Market Index Fund | 0.12% | 91,183 | 1.13M | Sep 29, 2025 |
| Fidelity Concord Street Trust-Fidelity Series Total Market Index Fund | 0.09% | 68,315 | 845.74K | Sep 29, 2025 |
| Fidelity Concord Street Trust-Fidelity Nasdaq Composite Index Fund | 0.06% | 48,351 | 598.59K | Sep 29, 2025 |